+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands



Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands



Bmc Infectious Diseases 13: 75



Infection with HPV 16 and 18, the major causative agents of cervical cancer, can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines provide cross-protection against HPV-types not included in the vaccines. In particular, the bivalent vaccine provides additional protection against HPV 31, 33, and 45 and the quadrivalent vaccine against HPV31. The quadrivalent vaccine additionally protects against low-risk HPV type 6 and 11, responsible for most cases of genital warts. In this study, we made an analytical comparison of the two vaccines in terms of cost-effectiveness including the additional benefits of cross-protection and protection against genital warts in comparison with a screening-only strategy. We used a Markov model, simulating the progression from HPV infection to cervical cancer or genital warts. The model was used to estimate the difference in future costs and health effects of both HPV-vaccines separately. In a cohort of 100,000 women, use of the bivalent or quadrivalent vaccine (both at 50% vaccination coverage) reduces the cervical cancer incidence by 221 and 207 cases, corresponding to ICERs of €17,600/QALY and €18,900/QALY, respectively. It was estimated that the quadrivalent vaccine additionally prevents 4390 cases of genital warts, reducing the ICER to €16,300/QALY. Assuming a comparable willingness to pay for cancer and genital warts prevention, the difference in ICERs could justify a slightly higher price (~7% per dose) in favor of the quadrivalent vaccine. Clearly, HPV vaccination has been implemented for the prevention of cervical cancer. From this perspective, use of the bivalent HPV vaccine appears to be most effective and cost-effective. Including the benefits of prevention against genital warts, the ICER of the quadrivalent HPV vaccine was found to be slightly more favourable. However, current decision-making on the introduction of HPV is driven by the primary cervical cancer outcome. New vaccine tenders could consider the benefits of cross-protection and the benefits of genital warts, which requires more balanced decision-making.

(PDF emailed within 0-6 h: $19.90)

Accession: 036757352

Download citation: RISBibTeXText

PMID: 23390964

DOI: 10.1186/1471-2334-13-75


Related references

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 27(35): 4776-4783, 2009

Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan. Bmc Health Services Research 10: 11, 2011

Vaccination: Protection for boys against genital warts and cancer via human papillomavirus infection. Der Urologe. Ausg. a 57(12): 1499-1508, 2018

The value of male human papillomavirus vaccination in preventing cervical cancer and genital warts in a low-resource setting. Bjog 123(6): 917-926, 2016

Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland. Plos One 12(5): E0177762, 2017

Cost-effectiveness analysis of Human Papillomavirus (HPV) vaccination in the Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion. Vaccine 28(4): 873-874, 2010

Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria. Vaccine 27(37): 5133-5141, 2009

A cost-effectiveness analysis of human papillomavirus vaccination of boys for the prevention of oropharyngeal cancer. Cancer 121(11): 1785-1792, 2015

Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. Journal of the National Cancer Institute 101(15): 1083-1092, 2009

Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. Bmc Medicine 7: 69, 2009

Effect of vaccination age on cost-effectiveness of human papillomavirus vaccination against cervical cancer in China. Bmc Cancer 16: 164, 2016

Effect of Vaccination Age on Cost-Effectiveness of Human Papillomavirus Vaccination Against Cervical Cancer in China. Value in Health 17(7): A724, 2014

Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. Bmc Infectious Diseases 17(1): 502, 2018

Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. Bmc Health Services Research 17(1): 353, 2018

Response: Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. Journal of the National Cancer Institute 102(5): 358-9; Author Reply 359-60, 2010